Alx Oncology's president & CSO sells $710k in stock

ALX Oncology Holdings Inc. (NASDAQ:ALXO) has reported a significant transaction involving its President and Chief Scientific Officer (CSO), Jaume Pons. According to a recent filing, Pons sold 50,000 shares of ALX Oncology common stock at prices ranging from $14.00 to $14.47, with the total transaction amounting to approximately $710,195.

The sale took place on April 16, 2024, and was conducted under a prearranged 10b5-1 trading plan, which was adopted by Pons on December 6, 2023. A 10b5-1 trading plan allows company insiders to sell a predetermined number of shares at a predetermined time to avoid accusations of insider trading.

In addition to the sale, the filing also disclosed that Pons exercised options to acquire 25,846 shares of common stock at a price of $0.99 per share, totaling around $25,587. The shares subject to the option were reported to be fully vested and immediately exercisable.

Following these transactions, the updated amount of common stock owned by Pons stands at 604,205 shares. ALX Oncology, based in South San Francisco, California, is a pharmaceutical company specializing in the development of therapies to improve patient care in oncology.

Investors and shareholders of ALX Oncology often monitor the buying and selling activities of company insiders such as executives and directors, as these transactions can provide insights into their confidence in the company's prospects and performance.

Amid the recent insider trading activity by ALX Oncology Holdings Inc.'s (NASDAQ:ALXO) President and CSO, Jaume Pons, the company's financials and stock performance have been a focal point for investors. ALXO's market cap stands at $789.39 million, reflecting the company's valuation in the biotechnology sector. Despite Pons' sale of shares, ALX Oncology has demonstrated a strong return over various periods, with a notable 1-year price total return of 245.06%. This could indicate investor optimism in the company's long-term potential.

However, the company's financial health reveals challenges. ALX Oncology's P/E ratio (adjusted) as of Q4 2023 is -4.91, which suggests that the market expects future earnings growth despite the company's current lack of profitability. Additionally, the company has an EBITDA of -$169.44 million, with a significant EBITDA growth decline of -33.32% in the same period, highlighting its operational losses.

InvestingPro Tips for ALXO reveal a mix of financial strengths and concerns. The company holds more cash than debt, providing some financial stability (InvestingPro Tip #0). However, analysts do not anticipate the company will be profitable this year (InvestingPro Tip #5), which is consistent with the negative earnings figures. For investors considering a deeper dive into ALX Oncology's potential, there are additional InvestingPro Tips available, offering insights such as the company's cash burn rate and gross profit margins. Get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro using the coupon code PRONEWS24.

Get The App

Join the millions of people who stay on top of global financial markets with Investing.com.

Download Now

Given the company's significant stock price movements and volatility (InvestingPro Tip #4), investors may want to monitor ALX Oncology's upcoming earnings report on May 8, 2024, for further indications of its financial trajectory and operational performance. With 12 more InvestingPro Tips listed for ALX Oncology, investors can access a comprehensive analysis to inform their investment decisions.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.